2023 World Conference on Lung Cancer (Posters)-P2.23. Prospective Observational Study of Cachexia and Its Effect on Systemic Therapy in Patients with Previously-Untreated Advanced NSCLC (NEJ050A)

P2.23. Prospective Observational Study of Cachexia and Its Effect on Systemic Therapy in Patients with Previously-Untreated Advanced NSCLC (NEJ050A) - PDF(Abstract)

Back to course

Pdf Summary

This presentation discusses the results of a prospective observational study that aimed to examine the effect of cachexia on systemic therapy in patients with previously-untreated advanced non-small cell lung cancer (NSCLC). The study also aimed to determine the incidence of cachexia in this patient population. The multicenter study included patients with advanced NSCLC and cachexia who were scheduled to start first-line systemic therapy. They were evaluated before and after the start of therapy using questionnaire surveys to assess the quality of life (QOL) related to appetite.<br /><br />The study included a total of 186 patients, with 180 patients receiving first-line systemic therapy. The patients were divided into three cohorts based on the treatment regimen: targeted therapy, cytotoxic chemotherapy with immune checkpoint inhibitors, and immune checkpoint inhibitors alone. The study found that the trends in QOL related to appetite differed depending on the type of first-line systemic therapy. Patients in the cohort receiving cytotoxic chemotherapy had worse changes in QOL compared to those receiving targeted therapy or immune checkpoint inhibitors.<br /><br />Additionally, the study found that the incidence of cachexia in patients with previously-untreated advanced NSCLC was 32.4%. This suggests that a significant portion of patients with advanced NSCLC experience cachexia, which may impact their prognosis. The study also found differences in progression-free survival and overall survival among the three cohorts, with median overall survival being poorest in the cohort receiving targeted therapy.<br /><br />In conclusion, the study highlights the importance of considering cachexia and its impact on QOL and treatment outcomes in patients with advanced NSCLC. The findings suggest that different treatment regimens may have varying effects on QOL and prognosis in patients with cachexia.

Asset Subtitle

Naoki Furuya

Meta Tag

Speaker Naoki Furuya

Topic Multidisciplinary Care: Nursing & Allied Health

Keywords

cachexia

systemic therapy

advanced non-small cell lung cancer

prospective observational study

incidence of cachexia

quality of life

appetite

first-line systemic therapy

treatment regimens

progression-free survival